You are here

FDA Announces Recall of Valsartan-containing Products

An impurity has been found to be carcinogenic.

An impurity called N-nitrosodimethylamine (NDMA) was found in several of products containing valsartan, which is used to treat heart failure and high blood pressure. But not all products containing valsartan are being recalled. And the FDA said that because valsartan is used to treat serious medical condition, patients should keep on taking the recalled products until they have a replacement.

Based on some laboratory tests, researchers have determined that NDMA could cause cancer. “The presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured,” the FDA said in a press release.

More Headlines

iPSC Therapy Designed to Salvage Eye, Prevent Vision Loss
Health Outcomes Have No Improvement
Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures
Targeted Antibody for FGR3-Positive Mutation
Method Could Lead to Manufacturing Corneas for Transplants
First and Only Second-Generation TKI for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Potential Life-Saving Device Can be Implanted in 2-LB Babies
New Therapy for Patients With HCC Who Previously Received Nexavar
Aggressive Disease Represents Around 6% of All New Cases of NHL